Mikhail Blagosklonny is widely recognized for his extensive research on cancer. He is a professor at the Roswell Park Cancer Institute teaching oncology. He has held other positions prior to this in medicine. Mikhail worked at the Ordway Research Institute as a senior scientist and as an associate professor of medicine at the New York Medical College. He has advocated for the use of Rapamycin, an anti-aging drug for cancer patients. Rapamycin has many uses such as prevention of organ transplant rejection and a cancer drug. Its initial use was as an anti-fungal agent in the early years of discovery. However, there were discoveries on possession of more properties that could apply in treatment of other diseases. Mikhail has been in the forefront in conducting research on cancer therapies. He is committed to finding remedies to aging that has led to his advocacy in using rapamycin drug to increase human life span.
The drug has cited numerous benefits over time. It has immunosuppressant properties that make it very useful in organ transplants. While other drugs used to prevent organ rejection have adverse effects on the kidneys, rapamycin displays low toxicity on the kidneys. It is an excellent anti-rejection drug as identified in many research works. Due to its low toxicity towards the kidneys, the drug is also the best treatment for patients with hemolytic-uremic syndrome. This rare disease’s best treatment is through kidney transplant. It reduces the probability of the kidney contracting the disease after transplant. The benefits of rapamycin and its contribution towards longevity of life have been influential in Mikhail’s advocacy. Rapamycin is a cure for lymphangioleiomyomatosis that is a rare lung disease. It is also used as a coating of the coronary stents in order to prevent occurrence of re-stenosis. It has also been proven to reduce risks of cancer patients by enhancing immune responses of the body towards tumors.
Mikhail Blagosklonny has conducted research and tests to find out whether rapamycin increases longevity of humans. Initial tests on aging mice proved that the drug enhanced their ability to resist tuberculosis. He believes that the drug can increase human life span hence continues to conduct more research on the subject. Mikhail is in the process of conducting research to prove whether rapamycin can be an effective treatment for Alzheimer, muscular dystrophy and systemic lupus erythematous. He is also conducting research on the longevity of persons. Mikhail has taken keen interest in this area having conducted extensive research on aging. He conducted initial test on elderly patients by administering rapamycin before influenza vaccination that showed rejuvenation. However, it is not evident whether the drug increases longevity. He is committed to ensuring that all individuals are able to access the best treatment globally. Mikhail Blagosklonny is keen on finding out why cancer commonly affects individuals of a certain age group. He is interested in identifying the connection between age and cancer prevalence. He is dedicated to ensuring that treatment of cancer will be affordable to all individuals.